Health Headlines: Weight-Loss Drug Updates, Insurance Changes, and Vape Smuggling

Current health news includes updates on Novo Nordisk's weight-loss drug CagriSema, U.S. health insurers working to simplify prior authorization, a firm funneling illegal Chinese vapes into the U.S., and Eli Lilly's experimental obesity pill results expected this quarter.

Novo Nordisk's latest trials show their weight-loss drug, CagriSema, has mild side effects with significant weight loss results. Despite positive outcomes, investor concerns led to a drop in shares. The company's top management saw changes with the ousting of CEO Lars Fruergaard Jorgensen.

Efforts to streamline U.S. health insurance procedures are underway. America's Health Insurance Plans announced plans for simplified, standardized electronic prior authorization processes, targeting completion by 2027 to improve patient and provider experiences.

Smuggling of illegal vapes into the U.S. shows how a small firm near Chicago aids in the illicit flow of Chinese e-cigarettes, revealing vulnerabilities in regulatory enforcement. Meanwhile, Eli Lilly is geared up for revealing obesity drug results, eyeing regulatory approvals by year-end.

(With inputs from agencies.)